Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study - Hirschfield, G.; Boudes, P.; Bowlus, C.; Gitlin, N.; Michael, G.; Harrison, S.; Gordon, S. C.; Aspinall, R.; Doerffel, Y.; Kremer, Andreas; Sheridan, D.; Bacon, B.; et al. (JOURNAL OF HEPATOLOGY, 2018)
CRIS-Team WoS Importer:2019-03-26